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Introduction
The most frequent target of chromosomal translocations in acute
myeloid leukemia (AML) is the Runt-related transcription factor
RUNX1/AML1, a key regulator of hematopoiesis (Setoguchi et al.,
2008; Pabst and Mueller, 2007; Growney et al., 2005; Ito, 2004;
Nucifora and Rowley, 1995; Romana et al., 1995). RUNX1/AML1
directly regulates multiple distinct myeloid and lymphoid genes that
are involved in hematopoietic lineage commitment (Huang et al.,
2007; Otto et al., 2003; Frank et al., 1995; Nuchprayoon et al., 1994).
The protein contains an N-terminal DNA-binding domain (runt-
homology domain) and a C-terminal regulatory domain that contains
a nuclear-matrix-targeting signal (NMTS) and several context-
dependent transcriptional activation or repression domains (Wheeler
et al., 2000; Meyers and Hiebert, 2000; Stein et al., 1999).
The 8;21 leukemic translocation fuses the RUNX1/AML1 gene
to MTG8/ETO coding sequences resulting in the AML1-ETO fusion
protein (Miyoshi et al., 1993; Erickson et al., 1992; Licht, 2001;
Davis et al., 2003; Peterson et al., 2007a). AML1-ETO retains the
DNA-binding function of the RUNX1/AML1 protein but does not
contain the transactivation domain or the nuclear-matrix-targeting
signal (NMTS) of RUNX1/AML1 (Zeng et al., 1997; McNeil et
al., 1999). Previous studies have shown that exogenously expressed
RUNX1/AML1 and AML1-ETO exhibit differential subnuclear
targeting, which might be responsible in part for the aberrant
function of the fusion protein (McNeil et al., 1999; Barseguian et
al., 2002). Altered subnuclear targeting of AML1 in patients with
the 8;21 translocation might contribute to the pathology of AML,
because RUNX1/AML1 mutations that alter subnuclear routing and
fidelity of transcriptional control result in a differentiation block
and increase proliferation of myeloid progenitors (Vradii et al., 2005;
Zaidi et al., 2007; Zaidi et al., 2005). In addition, a large number
of co-factors interact with gene regulatory domains of
RUNX1/AML1, including the C-terminus that is removed in
AML1-ETO (Wotton et al., 1994; Giese et al., 1995; Hiebert et al.,
1996; Rhoades et al., 1996; Petrovick et al., 1998; Rubnitz and Look,
1998; Osato et al., 1999). Through the recruitment of unique co-
regulators that interact with the ETO moiety in lieu of the AML1
C-terminus, the AML1-ETO fusion protein antagonizes the
transcriptional function of native RUNX1/AML1 (Hiebert et al.,
2001). Thus, there are several plausible mechanisms by which the
pathological formation of the AML1-ETO protein could block
differentiation of myeloid progenitors and promote leukemia.
In addition to regulating hematopoiesis-specific genes,
RUNX1/AML1 is also implicated in the regulation of cell-cycle
genes, including p21WAF1/CIP1, which encodes a cyclin-dependent
kinase inhibitor important for checkpoint control and terminal
differentiation (Lutterbach et al., 2000; Peterson et al., 2007b).
RUNX1/AML1 controls cell cycle progression by shortening the
G1-S phase in hematopoietic cells and is negatively regulated by
cyclin D3 (Strom et al., 2000; Peterson et al., 2005). Levels of
RUNX1/AML1 is required for definitive hematopoiesis and is
frequently targeted by chromosomal translocations in acute
myeloid leukemia (AML). The t(8;21)-related AML1-ETO
fusion protein blocks differentiation of myeloid progenitors.
Here, we show by immunofluorescence microscopy that during
interphase, endogenous AML1-ETO localizes to nuclear
microenvironments distinct from those containing native
RUNX1/AML1 protein. At mitosis, we clearly detect binding
of AML1-ETO to nucleolar-organizing regions in AML-derived
Kasumi-1 cells and binding of RUNX1/AML1 to the same
regions in Jurkat cells. Both RUNX1/AML1 and AML1-ETO
occupy ribosomal DNA repeats during interphase, as well as
interact with the endogenous RNA Pol I transcription factor
UBF1. Promoter cytosine methylation analysis indicates that
RUNX1/AML1 binds to rDNA repeats that are more highly
CpG methylated than those bound by AML1-ETO.
Downregulation by RNA interference reveals that
RUNX1/AML1 negatively regulates rDNA transcription,
whereas AML1-ETO is a positive regulator in Kasumi-1 cells.
Taken together, our findings identify a novel role for the
leukemia-related AML1-ETO protein in epigenetic control of
cell growth through upregulation of ribosomal gene
transcription mediated by RNA Pol I, consistent with the
hyper-proliferative phenotype of myeloid cells in AML patients.
Key words: Acute myelogenous leukemia, RUNX1, Ribosomal DNA
transcription, RNA polymerase I, UBF1, Nucleolar organizing region
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RUNX1/AML1 increase as cells progress into S phase and are
downregulated at the G2-M transition (Bernardin-Fried et al., 2004;
Biggs et al., 2006). The closely related osteoblastic transcription
factor RUNX2 also controls proliferation and is cell cycle regulated
with maximal levels in G1 (Pratap et al., 2003; Galindo et al., 2005).
Furthermore, the presence of RUNX2 in osteogenic mesenchymal
cells during mitosis might reinforce cell fate through an epigenetic
mechanism that retains phenotypic gene expression patterns after
cell division (Young et al., 2007b; Young et al., 2007a). Because
RUNX1/AML1 has also been detected during mitosis (Zaidi et al.,
2003), it could perform an analogous function in hematopoietic cells.
In this study, we examined the biological functions of
RUNX1/AML1 and AML1-ETO during mitosis and interphase in
relation to their subcellular localization in hematopoietic cells.
Among the main findings from our study is the observation that
both proteins can associate with mitotic chromosomes and regulate
transcription of ribosomal RNA genes, a fundamental process that
supports the growth of cells and is tightly coupled with cell
differentiation. Our results indicate that RUNX1/AML1 mediates
epigenetic mechanisms that convey regulatory information to
progeny cells and that these mechanisms are perturbed by the
leukemia related AML1-ETO fusion protein.
Results
During interphase RUNX proteins localize in nuclear micro-
environments where the transcriptional machinery is organized. As
cells emerge from mitosis there is a stringent requirement for
expression of RUNX1/AML1-responsive genes. Although
RUNX1/AML1 is destabilized during the G2-M transition
(Bernardin-Fried et al., 2004), at least a subset of RUNX1/AML1
remains associated with mitotic chromosomes (Zaidi et al., 2003).
However, many AML patients express the AML1-ETO fusion
protein and the important question arises whether this leukemia-
associated protein is similarly capable of interacting with mitotic
chromosomes.
Endogenous RUNX1/AML1 and AML1-ETO are targeted to
distinct nuclear microenvironments
To begin examining the localization of AML1-ETO during
interphase and mitosis, we used immunofluorescence microscopy
to monitor the subcellular distribution of endogenously expressed
RUNX1/AML1 and AML1-ETO in asynchronously growing
Kasumi-1 cells that were derived from an AML patient with an
8;21 chromosomal translocation (Fig. 1). Double-label comparisons
of immunofluorescence signals revealed the absence of a significant
overlap in the distribution patterns of RUNX1/AML1 and AML1-
ETO, and most sites were detected as distinct green or red
immunofluorescence signals (Fig. 1). Biochemical fractionation of
Kasumi-1 cells followed by immunoblotting validated the nuclear
distribution of RUNX1/AML1 and AML1-ETO (data not shown).
Hence, both RUNX1/AML1 and the AML1-ETO fusion protein
are predominantly present in the nucleus, but are each directed to
distinct subnuclear compartments. The distinct locations might
reflect differences in the regulatory activities of these factors in
leukemic cells.
RUNX1/AML1 and AML1-ETO are specifically associated with
metaphase chromosomes
To assess whether the leukemia-associated AML1-ETO fusion
protein interacts with mitotic chromosomes, we investigated its
presence in metaphase chromosomes by immunofluorescence
microscopy (Fig. 2). We first examined the association of
RUNX1/AML1 and AML1-ETO with mitotic chromosomes by
transfecting actively growing HeLa cells with epitope-tagged
expression constructs. Immunofluorescence microscopy reveals that
ectopically expressed RUNX1/AML1 and AML1-ETO each
associate with chromosomes in mitotic cells and are detected as
paired foci (Fig. 2A). The pair-wise organization of these foci is
similar to that reported for RUNX2 during mitosis (Young et al.,
2007a).
To determine the endogenous cellular organization of
RUNX1/AML1 and AML1-ETO proteins during mitosis, we
prepared metaphase chromosome spreads for human Jurkat cells
endogenously expressing RUNX1/AML1, HEL cells exhibiting
physiological expression of ETO, and Kasumi-1 cells expressing
the AML1-ETO translocation fusion protein. Endogenous
RUNX1/AML1 (in Jurkat cells) and AML1-ETO (in Kasumi-1
cells) each show distinct paired foci on metaphase chromosome
spreads, whereas ETO (in HEL cells) is not detected (Fig. 2B).
Interestingly, RUNX1/AML1 cannot be detected on mitotic
chromosomes in Kasumi-1 cells (data not shown), suggesting that
AML1-ETO might exclude RUNX1/AML1 from its sites at mitosis
(see below). Regardless of this possibility, our data clearly show
that AML1-ETO specifically associates with mitotic chromatin in
human leukemia cells, and thus provide the first indication that
AML1-ETO interferes with the normal function of RUNX1/AML1
at mitosis.
RUNX1/AML1 and AML1-ETO each bind to human ribosomal
DNA
The symmetrical pairing of large foci containing RUNX1/AML1
and AML1-ETO on mitotic chromosomes is reminiscent of previous
results with osteoblasts showing mitotic association of RUNX2 with
nucleolar-organizing regions (NORs) that represent sites containing
Journal of Cell Science 121 (23)
Fig. 1. RUNX1/AML1 and AML1-ETO are targeted to distinct subnuclear
locations. Immunofluorescence microscopy for endogenous RUNX1/AML1
(red) and AML1-ETO (green) with DAPI staining (blue) in Kasumi-1 cells as
well as merged images are shown. RUNX1/AML1 and AML1-ETO fusion
protein are predominantly present in the nucleus but do not colocalize in the
Kasumi-1 cells. An antibody detecting ETO was used to visualize the AML1-
ETO fusion protein, whereas an antibody recognizing the C-terminal domain
of RUNX1/AML1 was used to detect endogenous RUNX1/AML1.
Jo
ur
n
a
l o
f C
el
l S
cie
nc
e
3983AML1-ETO controls RNA transcription
tandemly repeated ribosomal DNA (rDNA) genes (Young et al.,
2007a). Therefore, we postulated that RUNX1/AML1 and AML1-
ETO may also bind to NORs and ribosomal repeats during
mitosis in hematopoietic cells. We performed chromatin
immunoprecipitation (ChIP) assays with primers spanning rDNA
sequences to determine in vivo occupancy of rDNA repeats by
RUNX1/AML1 and AML1-ETO in Kasumi-1 and Jurkat cells (Fig.
3A). The RNA Pol I regulatory protein upstream binding factor 1
(UBF1), which binds directly to rDNA and to mitotic NORs, was
used as a positive control for ChIP assays. Quantitative PCR data
showed that AML1-ETO occupies rDNA repeats during mitosis in
Kasumi-1 cells. However, association of RUNX1/AML1 to the
rDNA genes was barely detectable (Fig. 3B), consistent with the
immunofluorescence data (see results above). For comparison,
Jurkat cells that have high levels of RUNX1/ AML1 but do not
express the AML1-ETO fusion protein showed rDNA occupancy
by RUNX1/AML1 but not AML1-ETO, as expected (Fig. 3C).
Thus, these biochemical data establish that RUNX1/AML1 (in
Jurkat cells) and the AML1-ETO fusion protein (in Kasumi-1 cells)
are each associated with rDNA repeats during mitosis and were
visualized as NORs by immunofluorescence microscopy (see Fig.
2). Clear detection of the binding of AML1-ETO but not
RUNX1/AML1 to mitotic chromosomes in Kasumi-1 cells indicates
that AML1-ETO perturbs the normal function of RUNX1/AML1
during mitosis.
Because RUNX1/AML1 and AML1-ETO bind to rDNA repeats
during mitosis, we used ChIP assays to examine whether these
proteins are still capable of association during interphase in Kasumi-
1, HEL and Jurkat cells. As positive controls, we showed that the
RNA Pol I factor UBF1 interacted with rDNA repeats in all three
cell types (Fig. 4). The native ETO protein endogenously expressed
in HEL cells was not associated with the rDNA repeats, nor was
ETO detected on rDNA repeats in Jurkat cells that expressed neither
ETO nor the AML1-ETO fusion protein (Fig. 4A,B). Of note we
observed that both RUNX1/AML1 and AML1-ETO occupied
rDNA repeats in Kasumi-1 cells during interphase (Fig. 4C). The
latter finding suggests that RUNX1/AML1 and AML1-ETO are
concurrently bound to rDNA genes during interphase.
RUNX1/AML1 and AML1-ETO associate with UBF1 on rDNA
repeats in vivo
Our finding that RUNX1/AML1, AML1-ETO and UBF1 each
associate with rDNA repeats suggested that RUNX1/AML1 and
AML1-ETO interact with UBF1 in vivo. We carried out co-
immunoprecipitation assays to examine directly whether UBF1 is
present in a protein complex with RUNX1/AML1 or AML1-ETO.
AML1-ETO and RUNX1/AML1 were detected in
immunoprecipitates obtained with a UBF1 antibody (Fig. 5A). To
validate these results, reciprocal immunoprecipitation assays with
antibodies against RUNX1/AML1 and AML1-ETO were
performed. Indeed, UBF1 precipitated when immunocomplexes
were prepared using either RUNX1/AML1 or ETO antibodies (Fig.
5B). We also observe colocalization, albeit limited, of both
RUNX1/AML1 and AML1-ETO with nucleolar UBF1 during
interphase using immunofluorescence microscopy (Fig. 5C). Thus,
RUNX1/AML1 and AML1-ETO each associate with UBF1,
consistent with the interaction of these proteins with the regulatory
sequences of rDNA repeats.
To demonstrate that both RUNX1/AML1 and AML1-ETO bind
directly to the rDNA repeats, we conducted electrophoretic mobility
shift assays with a human rDNA probe spanning a RUNX-binding
element and nuclear extracts from Kasumi-1 cells. Competition assays
Fig. 2. RUNX1/AML1 and AML1-ETO associate with
metaphase chromosomes in pairs. (A) Epitope-tagged
RUNX1/AML1 and AML1-ETO were examined by in
situ immunofluorescence in HeLa cells and metaphase
cells were visually selected. RUNX1/AML1 and AML1-
ETO foci (green) are associated with chromosomes (blue)
in pairs (shown in deconvoluted images). (B) Mitotic
chromosome spreads were prepared for human Jurkat,
HEL and Kasumi-1 cells and processed for
immunofluorescence microscopy using antibodies
directed against the RUNX1/AML1, ETO and AML1-
ETO proteins. RUNX1/AML1 and AML1-ETO show
distinct foci on the mitotic chromosome spreads, whereas
ETO is not detected on mitotic chromosomes. Panels
above each image show enlargements of the areas labeled
with numbers.
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with 100-fold molar excess of unlabeled wild type, mutant or RUNX
consensus oligonucleotide were performed to establish the specific
protein-DNA complex (Fig. 5D). Addition of antibodies against
RUNX1 or AML1-ETO resulted in retarded mobility (supershift) of
the complex (Fig. 5D). These results indicate that RUNX1 and
AML1-ETO can interact with RUNX elements in the rDNA repeat.
To assess whether RUNX1/AML1 or AML1-ETO co-occupy
rDNA repeats with the RNA Pol I transcription factor UBF1, ChIP-
reChIP assays were performed in asynchronous Kasumi-1 cells.
UBF1 antibody was used for the primary ChIP, followed by a second
immunoprecipitation (reChIP) with either non-immune IgG (as a
negative control) or antibodies against UBF1, RUNX1/AML1 or
AML1-ETO. Quantitative PCR data showed that at least some
UBF1-bound rDNA fragments are also bound to RUNX1/AML1
or AML1-ETO proteins (Fig. 5E). These results indicate that
RUNX1/AML1 and AML1-ETO have a limited but significant
presence on ribosomal DNA repeats that interact with UBF1 in vivo.
AML1-ETO occupancy of rDNA repeats is correlated with DNA
hypomethylation and altered histone H3 methylation
It is well established that only a subset of rRNA genes are
transcriptionally active at any one time (Grummt and Pikaard, 2003).
We therefore investigated whether genomic occupancy of rDNA
repeats by RUNX1/AML1 or AML1-ETO is linked to epigenetic
chromatin modification. To monitor the association of
RUNX1/AML1 and AML1-ETO at methylated and unmethylated
rRNA genes, we used the ChIP-CHOP assay (Lawrence et al., 2004).
Chromatin from Kasumi cells was immunoprecipitated with
antibodies against RUNX1 or AML1-ETO (ChIP) and the resulting
DNA was digested with McrBC enzyme (CHOP) prior to qPCR
using rDNA primers. Only DNA that is methylated at two or more
cytosines (within 55-3000 bp) was digested by McrBC. We found
that rDNA regulatory regions associated with RUNX1/AML1 were
sensitive to digestion with the McrBC enzyme (Fig. 6, primers A
and B), whereas those associated with AML1-ETO are not.
Interestingly, the 18S rRNA coding region detected by primer C
was equally sensitive to McrBC in both RUNX1/AML1- and
AML1-ETO-bound fractions. Taken together, our results indicate
that rDNA repeats bound by RUNX1/AML1 are hyper-methylated
relative to those that are bound by AML1-ETO (Fig. 6).
We next investigated the presence of AML1-ETO relative to
post-translational modifications of nucleosomal histones. By
immunofluorescence microscopy of Kasumi cells we observed
significant colocalization of histone H3 dimethyl lysine 27
(H3K27me2) with AML1-ETO foci on mitotic chromosomes (Fig.
7A). There was limited colocalization with H3K9me2 and none
Journal of Cell Science 121 (23)
Fig. 3. AML1-ETO shows enhanced occupancy of rDNA repeats during
mitosis. (A) Schematic of the RUNX consensus elements (ovals) in the human
rDNA repeats depicting the locations of primers used for ChIP analysis.
(B,C) ChIPs were done with antibodies for RUNX1/AML1, ETO and UBF1,
as well as non-immune IgG in Kasumi-1 and Jurkat cells blocked in mitosis.
An antibody detecting ETO was used to immunoprecipitate the AML1-ETO
fusion protein, whereas an antibody recognizing the C-terminal domain of
RUNX1/AML1 was used to pull down endogenous RUNX1/AML1.
Quantitative PCR data are normalized to genomic DNA and denoted as
percent input (note that y-axis scales vary).
Fig. 4. Both RUNX1/AML1 and AML1-ETO occupy rDNA repeats in
interphase Kasumi-1 cells. Chromatin immunoprecipitation was done in
asynchronously growing HEL, Jurkat and Kasumi-1 cells using
RUNX1/AML1, ETO, UBF1 and IgG antibodies. Three different PCR primer
sets spanning RUNX consensus elements were used (see Fig. 3). (A,B) An
antibody detecting ETO was used to immunoprecipitate the AML1-ETO
fusion protein, whereas an antibody recognizing the C-terminal domain of
RUNX1/AML1 was used to pull down endogenous RUNX1/AML1.
Quantitative PCR data show that endogenous ETO does not bind to rDNA
repeats in HEL cells nor in Jurkat cells (where ETO is not expressed), whereas
UBF1 occupies the rDNA repeats in vivo in all the three cell lines tested.
(C) RUNX1/AML1 and AML1-ETO both occupy rDNA repeats in Kasumi-1
cells. Quantitative PCR data are normalized to genomic DNA and denoted as
percent input (note that y-axis scales vary).Jo
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with H3K4me2. We also performed ChIP assays to monitor
modified histones on rDNA repeats in Kasumi-1 cells that express
AML1-ETO and RUNX1/AML1 or in Jurkat cells that express only
RUNX1/AML1. We found that methylation of H3K4 was higher
for rDNA repeats in Jurkat cells whereas the presence of AML1-
ETO in Kasumi cells correlated with histone H3K27 methylation
on the ribosomal genes (Fig. 7B). The function of H3K27
methylation in Pol I transcription remains to be established. Taken
together, our results suggest that the presence of AML1-ETO at
ribosomal genes results in epigenetic alterations that reflect the
pathological consequences of the 8;21 translocation.
RUNX1/AML1 and AML1-ETO have opposing effects on
ribosomal biogenesis
We addressed the functional relevance of rDNA occupancy by
RUNX1/AML1 and AML1-ETO using RNA interference. Small-
interfering RNAs (siRNAs) specifically targeted against the mRNA
junction sequences of the AML1-ETO fusion protein (Heidenreich
et al., 2003) selectively reduced AML1-ETO protein levels by 50-
80% without affecting RUNX1/AML1 levels in Kasumi-1 cells (Fig.
8). Conversely, RUNX1/AML1 siRNAs specifically downregulated
RUNX1/AML1 protein levels by 50-80% without any effect on
AML1-ETO (Fig. 8A). Neither RUNX1 nor AML1-ETO protein
was affected by control siRNAs. Quantitative analysis revealed that
pre-rRNA synthesis is decreased significantly by depletion of
AML1-ETO in Kasumi-1 cells. By contrast, downregulation of
RUNX1/AML1 protein markedly increased pre-rRNA synthesis
(Fig. 8B). In neither case did we observe major changes in the large
pre-existing pools of total 28S rRNA. As a positive control, we
assessed mRNA levels of the CDK inhibitor p21, which is
upregulated by AML1-ETO (Peterson et al., 2007b), whereas
RUNX1/AML1 represses transcription of the p21 gene (Lutterbach
et al., 2000). Consistent with prior findings, our qPCR analysis
indicates that p21 levels are downregulated upon depletion of
AML1-ETO, whereas RUNX1/AML1 siRNA treatment increases
p21 mRNA levels. To rule out an indirect cell cycle effect resulting
from changes in p21 levels, we directly depleted p21 mRNA by
RNAi and found no effect on pre-rRNA expression (Budde and
Grummt, 1999) (also data not shown). Thus, both RUNX1/AML1
and AML1/ETO levels control pre-rRNA synthesis, but have
opposing effects.
To further examine the role of RUNX1/AML1 and AML1-ETO
in regulation of ribosomal genes, we electroporated epitope-tagged
RUNX1/AML1 and AML1-ETO into mouse 32D myeloid
progenitor cells. The expression of the exogenous proteins was
confirmed by immunoblotting with specific antibodies (Fig. 8C).
Fig. 5. Endogenous RUNX1/AML1 and AML1-ETO interact with UBF1 on the rDNA repeats. (A) Immunoprecipitation analysis was carried out with an antibody
for UBF1 followed by western blotting with AML1-ETO- and RUNX1/AML1-specific antibodies. Both RUNX1 and AML1-ETO are detected in western blot
analysis, however AML1-ETO shows greater interaction with UBF1 when compared with RUNX1/AML1. (B) Endogenous RUNX1/AML1 and AML1-ETO were
immunoprecipitated from Kasumi-1 cells using rabbit polyclonal antibodies that specifically recognize the C-terminus of RUNX1/AML1 or the ETO moiety. A
mouse monoclonal antibody was used to detect endogenous UBF1 by immunoblotting. UBF1 and IgG heavy chain are indicated. (C) Immunofluorescence
microscopy was performed in Kasumi-1 cells to detect endogenous RUNX1/AML1 (green), UBF1 (red) or AML1-ETO (green) with DAPI staining (blue). There
is colocalization, albeit limited, of both RUNX1/AML1 and AML1-ETO with nucleolar UBF1 during interphase. (D) Electrophoretic mobility shift assays were
performed with a human rDNA probe spanning a RUNX-binding element and nuclear extracts from Kasumi-1 cells. Competition assays with 100-fold molar
excess of unlabeled wild-type, mutant or RUNX consensus oligonucleotide were performed to establish the specific protein-DNA complex (left) as indicated.
Super-shift immunoassays were performed by incubating binding reactions with the indicated antibodies (right). Normal IgG was used as a negative control
(control). The arrow on the right indicates the supershift band. (E) ChIP-reChIP assays with endogenous proteins in interphase Kasumi-1 cells using UBF1
antibody (primary ChIP) and second immunoprecipitation (reChIP) with antibodies directed against UBF1, RUNX1/AML1, AML1-ETO or IgG. The re-ChIP data
are plotted as a percentage immunoprecipitation of the primary ChIP (set as 100%). Each of the regions was immunoprecipitated with similar efficiency in the
primary ChIP. These results show that RUNX1/AML1 and AML1-ETO each can co-occupy rDNA repeats with UBF1.
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Total cellular RNA from transfected cells was isolated and quantified
by RT-qPCR. The results reveal that pre-rRNA synthesis is
significantly increased by exogenous expression of AML1-ETO,
but forced expression of RUNX1/AML1 diminishes pre-rRNA
levels (Fig. 8C). Together, the RNAi and forced expression studies
demonstrate that RUNX1/AML1 negatively regulates rDNA
transcription, whereas AML1-ETO is a positive regulator.
Discussion
Using immunofluorescence microscopy and chromatin
immunoprecipitation, we have shown here that the leukemia-related
AML1-ETO fusion protein and the native RUNX1/AML1 factor
associate with ribosomal gene loci on mitotic chromosomes at nuclear-
organizing regions, the precursors to interphase nucleoli. This
principal finding provides the first indication that these regulatory
proteins contribute to epigenetic control of ribosomal gene expression
in pre-leukemic and leukemic cells in part by ‘book-marking’ these
genes during mitosis. Decreased interaction of RUNX1/AML1 with
mitotic chromosomes in AML-derived Kasumi-1 cells suggests that
AML1-ETO interferes with RUNX1/AML1 function not only during
interphase (Hiebert et al., 2001) but also during mitosis. Because
regulation of ribosomal RNA genes is a fundamental process that
supports the growth of cells and is tightly coupled with cell
differentiation, our findings have immediate ramifications for the
deregulation of growth control that is characteristic of cancer cells.
Transcription by RNA polymerase I regulates the rate of ribosome
biogenesis and the biosynthetic potential of the cell (Moss, 2004;
White, 2005). RNA Pol I activity is also tightly linked to the signals
that control cell growth, and a number of physiological and
pathological stimuli affect the rate of RNA Pol I transcription
(Russell and Zomerdijk, 2006). It is clear that cancer involves
significant changes to transcription factors, such as p53, that interact
with the Pol I complex (Grummt, 1999). The fact that elevated rRNA
synthesis has recently been shown to accelerate proliferation of
transformed cells (Zhao et al., 2003) provides further reason to believe
that ribosomal biogenesis has a profound impact on cancer biology.
We evaluated the functional roles for RUNX1/AML1 and the
leukemia-related AML1-ETO in rDNA transcription. Although
immunoprecipitation and immunofluorescence microscopy results
indicate that both proteins interact with UBF1 in interphase cells, the
combined results from our studies suggest that AML1-ETO and
RUNX1/AML1 perform opposing activities in control of ribosomal
gene transcription. Indeed, downregulation of RUNX1/AML1 or
AML1-ETO by RNA interference in Kasumi-1 cells reveals that
RUNX1/AML1 negatively regulates rDNA transcription, whereas
AML1-ETO is a positive regulator. Consistent with a negative role
for RUNX1/AML1 in ribosomal RNA synthesis we found that it binds
to highly methylated rDNA regulatory sequences. Additionally,
Kasumi-1 cells expressing the AML1-ETO fusion protein and Jurkat
cells that express only AML1 differ in post-translational epigenetic
marks of histone proteins at the rDNA repeats. Hence, our findings
suggest a novel pathological role for the leukemogenic AML1-ETO
protein in epigenetic regulation of cell growth through control of
RNA-Pol-I-mediated ribosomal gene transcription.
We also have observed that endogenous RUNX1/AML1, ETO
and AML1-ETO proteins are directed to distinct subcellular
compartments. In interphase cells, the AML1-ETO fusion protein
is localized in the nucleus but targeted to nuclear microenvironments
distinct from those containing endogenous RUNX1/AML1 protein.
Thus, as we previously reported for ectopically expressed
RUNX1/AML1 and AML1-ETO proteins (McNeil et al., 1999;
Barseguian et al., 2002), localization of the leukemia-related fusion
protein is deregulated both during interphase and mitosis. The
altered subnuclear location of AML1-ETO is a direct consequence
of the elimination of the RUNX1/AML1 targeting signal and the
addition of specific determinants residing in ETO that are fused to
AML1 during the t(8;21) chromosomal rearrangement. By contrast,
unlike the AML1-ETO protein, native ETO endogenously expressed
in HEL cells is excluded from mitotic chromosomes. Thus, the runt-
homology DNA-binding domain that is fused to ETO in the
chimeric AML1-ETO protein supports the recruitment of the ETO
moiety to the rDNA repeats to deregulate rDNA transcription.
RUNX1/AML1 is a scaffolding protein that recruits many co-
regulatory transcription factors to focally organized nuclear
microenvironments (Zaidi et al., 2007; Lian et al., 2004). Many of
these cofactors interact with the C-terminus of RUNX1/AML1 and
can support either repression or activation by RUNX1/AML1 (e.g.
TLE/Groucho, LEF1, CBP, p300 and MOZ) (reviewed by Durst
and Hiebert, 2004). The loss of the RUNX1/AML1 C-terminus in
the AML1-ETO fusion protein thus precludes the recruitment of a
large group of possible co-factors to rDNA repeats and other
RUNX1/AML1 target genes. Furthermore, the acquisition of ETO-
related protein-coding sequences in AML-ETO-expressing cells will
mediate the interactions of a distinct group of co-factors during
interphase and mitosis. For example, the AML1-ETO fusion protein
has been shown to aberrantly recruit co-repressor complexes (e.g.
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Fig. 6. RUNX1/AML1 associates with hypermethylated rDNA repeats.
Chromatin from Kasumi cells was immunoprecipitated with antibodies against
RUNX1/AML1 or AML1-ETO and the resulting DNA was digested with
McrBC enzyme prior to qPCR using indicated rDNA primers. An antibody
detecting ETO was used to immunoprecipitate the AML1-ETO fusion protein,
whereas an antibody recognizing the C-terminal domain of RUNX1/AML1
was used to pull down endogenous RUNX1/AML1. Quantitative PCR data are
normalized to genomic DNA and denoted as percentage input. These results
indicate that rDNA repeats bound by RUNX1/AML1 are hypermethylated
relative to those that are bound by AML1-ETO.Jo
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N-CoR–Sin3–HDAC1) to actively shut down transcription from
RUNX1/AML1 target genes important for normal hematopoiesis
(Hiebert et al., 2001). However, AML1-ETO does not always
function as a transcriptional repressor. For example, expression of
AML1-ETO has been shown to transactivate the BCL-2 and MDR1
promoters in reporter gene assays, although binding to a RUNX
element might not be necessary (Klampfer et al., 1996; Hines et
al., 2007; Burel et al., 2001). Additionally, AML1-ETO upregulates
C/EBPε to induce the expression of the G-CSF receptor and
synergistically activates the M-CSF receptor promoter in
combination with AML1 (Rhoades et al., 1996; Shimizu et al.,
2000). We propose that modified association of cofactors with rDNA
genes activates rDNA transcription in leukemia cells expressing the
8;21 fusion protein. However, the actual mechanism by which
AML1-ETO compromises fidelity of rDNA transcription may be
complex. An indirect mechanism that is not ruled out by our data
is that AML1-ETO binds to the regulatory element of another gene
that is responsible for activation of rDNA transcription.
In conclusion, there are two major implications of the results
presented in our study. First, the AML1-ETO fusion protein not
only affects RNA Pol II gene regulation but also RNA-Pol-I-
mediated ribosomal RNA transcription during interphase. Second,
AML1-ETO perturbs normal functions of RUNX1/AML1 in mitotic
cells to alter hematopoietic lineage-specific control of ribosomal
RNA genes in progeny cells. The current findings suggest that
AML1-ETO deregulates multiple gene regulatory pathways that
control growth, proliferation and lineage identity. The coordinated
deregulation of these intricate and biologically linked processes
might clarify the potent properties of AML1-ETO in altering normal
hematopoiesis and promoting development of leukemia.
Materials and Methods
Cell culture
The human erythroleukemia (HEL) cells and the t(8;21)-carrying cell line Kasumi-
1 were cultured in RPMI supplemented with 10% fetal bovine serum (FBS), 2 mM
L-glutamine and 100 U/ml penicillin and 100 μg/ml streptomycin. Cells were
Fig. 7. AML1-ETO presence on rDNA repeats correlates with altered histone H3 methylation. (A) AML1-ETO colocalizes with histone H3 dimethyl lysine 27
(H3K27) on mitotic chromosomes. Immunofluorescence microscopy with antibodies against post-translational modifications of nucleosomal histones in metaphase
spreads prepared from Kasumi-1 cells. The antibodies used to detect histone modifications were as follows: H3K9me2, H3K4me2 and H3K27me2. Each group of
five panels shows merged images co-stained with antibodies against AML1-ETO. The lower left panels in each group show DAPI staining only. The top three
panels in each group (indicated by numbers) show enlargements of the areas numbered on the lower right of each group. (B) AML1-ETO occupancy of rDNA
repeats is associated with histone H3 lysine 27 methylation (H3K27me2). ChIPs were performed with RUNX1/AML1, AML1-ETO, IgG and histone modification
antibodies were done in Jurkat (left panels) and Kasumi-1 cells (right panels). The antibodies used to detect histone modifications were as follows: Acetylated
histone H3 (Acet-H3), H3K4me2 and H3K27me2. Presence of AML1-ETO in Kasumi-1 cells correlates with elevated histone H3K27 methylation on the rDNA
repeats compared with Jurkat cells, which express only RUNX1/AML1.
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maintained at 37°C in a humidified atmosphere with 95% air, 5% CO2 at a
concentration between 0.5106 and 1106 cells/ml.
Plasmid constructs and transfection experiments
Constructs pCMV5-HA-AML1/ETO and pCMV5-HA-RUNX1/AML1 were used in
this study (Barseguian et al., 2002). HeLa cells were seeded in six-well culture plates
at a density of 1.5-2.0105 cells/well, and transient transfections were performed 24
hours later using FuGENE 6 according to the manufacturer’s instructions (Roche,
Indianapolis, IN). Cells were harvested 24 hours after transfection for
immunofluorescence microscopy. Amaxa nucleofection of HEL and Kasumi-1 cells
was performed according to the protocol suggested by the manufacturer (Amaxa,
Gaithersburg, MD). The immunostaining was performed using anti-HA antibody.
Metaphase spread preparation
For metaphase spread preparation, cells were incubated with colcemid (Invitrogen
Corporation, Carlsbad, CA) to a final concentration of 0.05 μg/ml at 37°C for 3-4
hours. Chromosome spreads were generated by incubating mitotic cells in 0.075 M
KCl solution for 20 minutes at 37°C, fixed with methanol to acetic acid (3:1 vol/vol),
dropped onto frosted glass microscope slides and air-dried.
Immunofluorescence microscopy
Cells were grown in regular growth medium for 1-2 days and then processed for in
situ immunofluorescence. 500 μl cell suspension were deposited onto glass slides in
a Shandon Cytospin 2 centrifuge. Cells were rinsed with ice-cold phosphate-buffered
saline (PBS) and fixed in 3.7% formaldehyde in PBS for 10 minutes on ice. After
rinsing once with PBS, the cells were permeabilized in 0.25% Triton X-100 in PBS,
rinsed twice in PBSA (0.5% bovine serum albumin in PBS) and stained with
antibodies. 
The following primary antibodies and dilutions were used: UBF rabbit polyclonal
(H-300), UBF mouse monoclonal (both 1:100; Santa Cruz Biotechnology); AML1
rabbit polyclonal (1:100; Active Motif), AML1 mouse monoclonal (1:100; 2B5
generous gift from Yoshiaki Ito, National University of Singapore, Singapore); ETO
rabbit polyclonal (1:100; Calbiochem, San Diego, CA). For localization of antigen-
antibody complexes, we used the following complementary fluorescent secondary
antibodies: Alexa Fluor 488 goat anti-rabbit IgG, Alexa Fluor 488 goat anti-mouse
IgG, and Alexa Fluor 594 goat anti-mouse IgG (1:800; Molecular Probes/Invitrogen).
Staining of cell preparations and chromosome spreads was recorded with a CCD
camera attached to an epifluorescence Zeiss Axioplan 2 (Zeiss, Thorwood, NY)
microscope. For interphase studies single image planes were acquired and
deconvoluted using the Metamorph Imaging Software (Universal Imaging,
Dowingtown, PA). For metaphase spreads Z-series image stacks were acquired at
0.25 μm intervals with 67 nm/pixel (x-y). Restoration of images was carried out by
3D deconvolution using a measured point-spread function as described previously
(Carrington et al., 1995).
Chromatin immunoprecipitation and analysis
Chromatin immunoprecipitation assays (ChIPs) were performed by crosslinking
asynchronously growing cells with 1% formaldehyde in RPMI for 10 minutes at
room temperature. Crosslinking was quenched by adding glycine to a final
concentration of 250 mM for 10 minutes. Cells were collected and washed twice
with PBS. Cell pellets were resuspended in 2.5 ml lysis buffer (150 mM NaCl, 50
mM Tris-HCl pH 8.0, 1% NP-40, 25 μM MG-132, and 1 Complete® protease
inhibitor cocktail (Roche). After 10 minutes on ice, cells were sonicated to obtain
DNA fragments of ~500 bp as determined by agarose gel electrophoresis with ethidium
bromide staining. Protein-DNA complexes were isolated by centrifugation at 15,000
rpm for 20 minutes. Supernatants with protein-DNA complexes were incubated for
16 hours with 3 μg rabbit polyclonal antibody directed against each protein. The
following primary antibodies were used: UBF rabbit polyclonal, ETO rabbit polyclonal
(Santa Cruz Biotechnology) and AML1 rabbit polyclonal (Active Motif). The
antibodies used to detect histone modifications were as follows: Acetylated histone
H3, dimethyl H3K4 and dimethyl H3K27 (Upstate Biotechnology, Lake Placid, NY).
Antibody-protein-DNA complexes were further incubated with 50-60 μl of 30%
protein A/G beads (Santa Cruz Biotechnology) to isolate antibody-bound fractions
of chromatin. Immunocomplexes were washed with the following buffers: low salt
(20 mM Tris-HCl pH 8.1, 150 mM NaCl, 1% Triton X-100, 2 mM EDTA, 1
complete protease inhibitor), high salt (20 mM Tris-HCl, pH 8.1, 500 mM NaCl, 1%
Triton X-100, 2 mM EDTA), LiCl (10 mM Tris-HCl, pH 8.1, 250 mM LiCl, 1%
deoxycholate, 1% NP-40, 1 mM EDTA) and twice in TE (10 mM Tris-HCl pH 8.1,
1 mM EDTA). Protein-DNA complexes were eluted in 1% SDS and 100 mM
NaHCO3. Crosslinks of pull-down fractions and inputs (2% of total IP fraction) were
reversed by incubation overnight in elution buffer and 0.2 M NaCl. DNA then was
extracted, purified, precipitated and resuspended in TE for qPCR. ChIP-reChIP
experiments were carried out essentially as described (Sinkkonen et al., 2005). Briefly,
UBF1 ChIP complexes were eluted in 10 mM DTT buffer for 30 minutes at 37°C,
diluted 1:40 in ChIP lysis buffer and subjected to a second immunoprecipitation (i.e.
re-ChIP) as described above. Quantitative PCR was done to quantify the
immunoprecipitated DNA as described previously (Frank et al., 2001). For ChIP-
CHOP PCR (Lawrence et al., 2004), 10% of the immunoprecipitated DNA was
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Fig. 8. RUNX1/AML1 or AML1-ETO deficiency alters
rRNA synthesis. Kasumi-1 cells were transfected with two
independent RUNX1/AML1 or AML1-ETO siRNAs or
non-silencing (NS) siRNA. (A) To check the efficiency of
knockdown, protein expression of RUNX1/AML1, AML1-
ETO and α-tubulin was examined by western blot analysis.
(B) Expression of unprocessed rRNA (pre-rRNA synthesis),
28S RNA and p21 was examined by RT-PCR analysis. Bars
represent expression levels relative to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) mRNA (± s.e.m.) from
three independent experiments performed in triplicate.
(C) Epitope-tagged RUNX1/AML1 and AML1-ETO were
each ectopically expressed in mouse 32D myeloid
progenitor cells. Pre-rRNA synthesis was measured by RT-
qPCR relative to GAPDH in equal numbers of cells (top).
Expression of the exogenous proteins was analyzed by
western blot analysis (bottom). EV, empty vector.
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digested with 10 U McrBC (New England Biolabs) in reaction buffer (50 mM NaCl,
10 mM Tris-HCl, 10 mM MgCl2, 1 mM dithiothreitol, 100 μg/ml bovine serum
albumin, 1 mM GTP pH 7.9) at 37°C for 2-3 hours. Quantitative PCR was done to
quantify the immunoprecipitated DNA as described previously. All ChIP and ChIP-
CHOP PCR experiments were repeated at least twice.
Co-immunoprecipitation analysis
Kasumi-1 cells (50-70% confluent) were used for co-immunoprecipitation studies as
described previously (Hassan et al., 2004). Equal amounts of cell lysate were
immunoprecipitated with antibodies for UBF1 (F-9 or H-300), ETO (H-54, Santa
Cruz Biotechnology) and AML1 (39000, Active Motif), overnight in phosphate-
buffered saline with 5 mM EDTA. After a 2 hour incubation with protein A/G beads
followed by three washes with PBS, the immunocomplexes were separated by 10%
SDS-PAGE and western blotted with the indicated antibodies.
Electrophoretic mobility shift assay 
Asynchronously growing Kasumi cells were harvested in ice-cold PBS buffer, cell
pellets were lysed, and nuclear extracts prepared. The following oligonucleotides
(double-stranded) representing wild-type (WT) and mutant (MT) RUNX binding
elements of the human rDNA promoter were synthesized: WT, GGCTATCT -
ATTTTGTGGTTAGAATAAAGTT; MT, GGCTATCTATTTTGTACTTAGAA -
TAAA GTT. The probes were end-labeled with [γ-32P]ATP by using T4 polynucleotide
kinase (New England Biolabs). Consensus and mutant oligonucleotides were used
as competitors. Nuclear protein extracts (5 μg) were incubated for 30 minutes at
room temperature with 1 μg nonspecific competitor DNA poly (dI·dC) (Pharmacia,
Piscataway, NJ) and 80,000 cpm of labeled oligonucleotides. Competition assays
were performed by mixing 100-fold molar excess of unlabeled oligonucleotides (wild
type or mutant) with nuclear extracts before addition of probes. RUNX1 and ETO
antibodies (2 μg each; Santa Cruz Biologicals) were used for super-shift experiments.
Normal rabbit IgG was used as a nonspecific control. Protein-DNA complexes were
visualized by autoradiography of 5% polyacrylamide gels.
RNA interference
Exponentially growing Kasumi-1 cells were electroporated using Amaxa Nucleofector
(Amaxa Biosystems) according to the manufacturer’s protocol, with siRNAs against
RUNX1/AML1 (Dharmacon, Lafayette, CO) or AML1-ETO, as described previously
(Heidenreich et al., 2003). A non-silencing siRNA (Qiagen) were used as a negative
control. Total RNA and protein were isolated for further analysis.
Quantitative reverse transcription-PCR (qRT-PCR)
RNA was extracted from all samples using TRIzol reagent (Invitrogen) according to
the manufacturer’s protocol. Purified total RNA was subjected to DNase I digestion,
followed by column purification using the DNA-free RNA Kit (Zymo Research,
Orange, CA). Eluted total DNA-free RNA was quantified by spectrophotometry and
1 μg was added to a reverse transcription reaction using the iScript cDNA synthesis
kit (Bio-Rad) with a mixture of random hexamers and oligo(dT) primers. Relative
quantification was determined using the ABI PRISM 7000 sequence detection system
(Applied Biosystems, Foster City, CA) measuring real-time SYBR Green supermix
fluorescence. The relative level of each mRNA was determined using the comparative
CT method for relative quantification using GAPDH or mCox as an endogenous
reference. Primer sets used here have been described previously (Young et al., 2007a).
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